(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.08%) $79.06
(-0.05%) $1.931
(0.87%) $2 331.00
(0.81%) $26.97
(1.03%) $964.70
(-0.45%) $0.933
(-0.66%) $11.02
(-0.31%) $0.798
(0.06%) $93.51
Quarter results today
(amc 2024-05-01)
Expected move: +/- 4.94%
Live Chart Being Loaded With Signals
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases...
Stats | |
---|---|
本日の出来高 | 664 375 |
平均出来高 | 502 818 |
時価総額 | 4.96B |
EPS | $0 ( 2024-02-21 ) |
次の収益日 | ( $-0.580 ) 2024-05-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -35.58 |
ATR14 | $0.283 (0.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Hoffmeister David F | Buy | 10 000 | Common Stock |
2024-04-10 | Hoffmeister David F | Sell | 10 000 | Stock Option (Right to Buy) |
2024-04-08 | Gilliam Joseph E | Buy | 59 801 | Common Stock |
2024-04-08 | Gilliam Joseph E | Sell | 10 456 | Common Stock |
2024-04-08 | Gilliam Joseph E | Sell | 41 068 | Common Stock |
INSIDER POWER |
---|
0.86 |
Last 100 transactions |
Buy: 501 923 | Sell: 495 631 |
ボリューム 相関
Glaukos Corp 相関 - 通貨/商品
Glaukos Corp 財務諸表
Annual | 2023 |
収益: | $314.71M |
総利益: | $239.14M (75.99 %) |
EPS: | $-2.78 |
FY | 2023 |
収益: | $314.71M |
総利益: | $239.14M (75.99 %) |
EPS: | $-2.78 |
FY | 2022 |
収益: | $282.86M |
総利益: | $213.88M (75.61 %) |
EPS: | $-2.09 |
FY | 2021 |
収益: | $294.01M |
総利益: | $227.38M (77.34 %) |
EPS: | $-1.070 |
Financial Reports:
No articles found.
Glaukos Corp
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。